Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Demographic characteristics of COVID-19 patients with bacterial infection_
| Overall sample (n = 300) | Mild group (n = 90) | Moderate group (n = 90) | Severe group (n = 120) | p-value | |
| Patient characteristics | |||||
| Median age (years) | 79 (59–92) | 79 (59–84) | 81 (68–89) | 78(69–92) | 0.578 |
| Sex (n (%)) | |||||
| Male | 240 | 60/90 (66.7%) | 80/90 (88.8%) | 100/120 (83.3%) | 0.001 |
| Female | 60 | 30/90 (33.3%) | 10/90 (11.1%) | 20/120 (16.6%) | 0.001 |
| Clinical symptoms | |||||
| Fever | 220 | 70/90 (77.8%) | 60/90 (66.7%) | 90/120 (75.0%) | 0.210 |
| Fatigue | 70 | 10/90 (11.1%) | 20/90(22.2%) | 40/120 (33.3%) | 0.001 |
| Difficulty breathing | 200 | 70/90 (77.8%) | 60/90 (66.7%) | 70/120 (58.3%) | 0.012 |
| Vomiting | 30 | 0 | 0 | 30/120 (25.0%) | < 0.001 |
| Cough and expectoration | 290 | 90/90 (100%) | 90/90 (100%) | 110/120 (91.7%) | < 0.001 |
Antibiotic susceptibility testing abbreviations_
| Abbreviation | Full Name |
|---|---|
| SAM | Ampicillin-sulbactam |
| TZP | Piperacillin-tazobactam |
| CZO | Cefazolin |
| CTT | Cefotetan |
| CAZ | Ceftazidime |
| CRO | Ceftriaxone |
| FEP | Cefepime |
| ATM | Aztreonam |
| ETP | Ertapenem |
| IPM | Imipenem |
| AMK | Amikacin |
| GM | Gentamicin |
| TOB | Tobramycin |
| CIP | Ciprofloxacin |
| LVX | Levofloxacin |
| SXT | Trimeth oprim-sulfameth oxazole |
| CSL | Cefoperazone-sulbactam |
| MEM | Meropenem |
| DOX | Doxycycline |
| MNO | Minocycline |
| TGC | Tigecycline |
| CS | Colistin |